MX2022004912A - Novedoso compuesto de anillo condensado sustituido. - Google Patents

Novedoso compuesto de anillo condensado sustituido.

Info

Publication number
MX2022004912A
MX2022004912A MX2022004912A MX2022004912A MX2022004912A MX 2022004912 A MX2022004912 A MX 2022004912A MX 2022004912 A MX2022004912 A MX 2022004912A MX 2022004912 A MX2022004912 A MX 2022004912A MX 2022004912 A MX2022004912 A MX 2022004912A
Authority
MX
Mexico
Prior art keywords
provides
condensed ring
ring compound
novel substituted
compound
Prior art date
Application number
MX2022004912A
Other languages
English (en)
Inventor
Sachiko Koike
Takayuki Fukaya
Shunichiro UESUGI
Yohei Ikuma
Original Assignee
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Co Ltd filed Critical Sumitomo Pharma Co Ltd
Publication of MX2022004912A publication Critical patent/MX2022004912A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Abstract

La presente invención proporciona un compuesto novedoso que tiene un excelente efecto inhibidor de ß-lactamasa; la presente invención proporciona: un compuesto que tiene un excelente efecto inhibidor de ß-lactamasa y está representado por la fórmula (1a), (1b) u (11); o una sal farmacéuticamente aceptable del mismo; este compuesto proporciona un agente profiláctico o terapéutico efectivo para infecciones bacterianas cuando se utiliza en combinación con fármacos a base de ß-lactama o se utiliza como un solo agente; la presente invención proporciona también un agente profiláctico o terapéutico efectivo para tratar varias enfermedades, al utilizarse en combinación con los fármacos a base de ß-lactama.
MX2022004912A 2019-10-25 2020-10-23 Novedoso compuesto de anillo condensado sustituido. MX2022004912A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019194753 2019-10-25
PCT/JP2020/039897 WO2021079984A1 (ja) 2019-10-25 2020-10-23 新規置換縮環型化合物

Publications (1)

Publication Number Publication Date
MX2022004912A true MX2022004912A (es) 2022-08-25

Family

ID=75619318

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004912A MX2022004912A (es) 2019-10-25 2020-10-23 Novedoso compuesto de anillo condensado sustituido.

Country Status (10)

Country Link
US (1) US20230038124A1 (es)
EP (1) EP4049680A4 (es)
JP (1) JPWO2021079984A1 (es)
KR (1) KR20220088736A (es)
CN (1) CN114929715A (es)
AU (1) AU2020371404A1 (es)
CA (1) CA3155559A1 (es)
MX (1) MX2022004912A (es)
TW (1) TW202130635A (es)
WO (1) WO2021079984A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202317085A (zh) * 2021-10-19 2023-05-01 大陸商上海濟煜醫藥科技有限公司 三環類硼酸衍生物及其製備方法和應用
WO2023155869A1 (zh) * 2022-02-18 2023-08-24 辉诺生物医药科技（杭州）有限公司 新的硼酸类化合物的晶型及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141391A1 (es) * 2011-08-17 2014-10-29 Glaxosmithkline Llc Combinacion que comprende un compuesto con actividad antiviral y un agente terapeutico
DK2744332T3 (en) * 2011-08-19 2017-01-16 Glaxo Group Ltd BENZOFURAN COMPOUNDS FOR TREATMENT OF HEPATITIS C VIRUS INFECTIONS
WO2014089365A1 (en) 2012-12-07 2014-06-12 Venatorx Pharmaceuticals, Inc Beta-lactamase inhibitors
US9642869B2 (en) 2013-01-04 2017-05-09 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2014107536A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9403850B2 (en) 2013-01-10 2016-08-02 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
BR112016026291A2 (pt) * 2014-05-19 2017-08-15 Rempex Pharmaceuticals Inc Derivados do ácido borônico e usos terapêuticos dos mesmos
WO2015191907A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
KR20170024087A (ko) 2014-07-01 2017-03-06 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
WO2016149393A1 (en) * 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA3026582A1 (en) 2016-06-30 2018-01-04 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2018199291A1 (ja) 2017-04-28 2018-11-01 大日本住友製薬株式会社 ヘテロ環誘導体
WO2019009370A1 (ja) 2017-07-06 2019-01-10 大日本住友製薬株式会社 アミド誘導体
WO2019009369A1 (ja) 2017-07-06 2019-01-10 大日本住友製薬株式会社 イミン誘導体
BR112020021631A8 (pt) * 2018-04-27 2023-02-28 The Kitasato Inst Composto oxo-substituído

Also Published As

Publication number Publication date
US20230038124A1 (en) 2023-02-09
CN114929715A (zh) 2022-08-19
EP4049680A1 (en) 2022-08-31
TW202130635A (zh) 2021-08-16
CA3155559A1 (en) 2021-04-29
EP4049680A4 (en) 2024-01-10
WO2021079984A1 (ja) 2021-04-29
JPWO2021079984A1 (es) 2021-04-29
AU2020371404A1 (en) 2022-05-19
KR20220088736A (ko) 2022-06-28

Similar Documents

Publication Publication Date Title
MX2021006265A (es) Derivados de panteteina y usos de los mismos.
MX2020002033A (es) Derivados heterociclicos condensados como inhibidores de bcl-2 para el tratamiento de enfermedades neoplasticas.
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
PH12020550168A1 (en) Griseofulvin compound and pharmaceutical use thereof
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
MX2020011873A (es) Nuevos derivados de quinolina.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
MX2020000576A (es) Compuestos quimicos.
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
MX2022004912A (es) Novedoso compuesto de anillo condensado sustituido.
MX2021012105A (es) Compuestos de pirrol.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
ZA202204442B (en) Salt forms of a complement component c5a receptor
MX2019006768A (es) Peptidos antimicrobianos.
SG11201907945YA (en) Azetidine derivative
PH12019502509A1 (en) Compounds and methods for treating bacterial infections
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
PH12020551772A1 (en) Oxo-substituted compound
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.
WO2020251871A3 (en) Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
EA202190316A1 (ru) Конденсированное производное лактама
MX2021007258A (es) Composiciones de esparsentan amorfas.
MX2021003485A (es) Derivados de indano para uso en el tratamiento de infeccion bacteriana.
ZA202205158B (en) Polypeptide having mmp2-inhibitory effect